Graham Walmsley

Dr. Walmsley serves as General Partner of Logos Capital and co-manages the firm’s private efforts. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies (including BlueRock Therapeutics acquired by Bayer), and was head of business development for Jecure Therapeutics through its acquisition by Roche. Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO), ALX Oncology (NASDAQ: ALXO), and Olema Pharmaceuticals (NASDAQ: OLMA). Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.